ArticleWorld journal of gastrointestinal oncology2025
Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver metastases are very common in pancreatic neuroendocrine tumors (pNETs). When surgical resection is possible, it is typically associated with survival benefits in patients with pNET and liver metastases. Patient-derived organoids are a powerful preclinical platform that show great potential for predicting treatment response, and they have been increasingly applied in precision medicine and cancer research. CASE SUMMARY: A 51-year-old man was admitted to the hospital with the chief complaint of intermittent dull pain in the upper abdomen for over 3 years. Computerized tomography showed multiple space-occupying lesions in the liver and a neoplasm in the pancreatic body. Pathological results suggested a grade 3 pancreas-derived hepatic neuroendocrine tumor. In combination with relevant examinations, the patient was diagnosed with pNET with liver metastases (grade 3). Transarterial chemoembolization was initially performed with oxaliplatin and 5-fluorouracil, after which the chemotherapy regimen was switched to liposomal irinotecan and cisplatin for a subsequent perfusion, guided by organoid-based drug sensitivity testing. Following interventional treatment, the tumor had decreased in size. However, due to poor treatment compliance and the patient's preference for surgical management, multiple resections were performed. Postoperatively, liposomal irinotecan combined with cisplatin was continuously admnistered. To date, the patient has survived 18 months with tumor presence, and tumor markers have returned to normal.
conclusionThis case suggests that patient-derived organoids can aid in the optimization of therapeutic decisions in pNET patients with liver metastases to guide personalized treatment and improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.